{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["loncastuximab tesirine","ibrutinib"]],"indication":"advanced diffuse large B-cell or mantle cell lymphoma","name":"LOTIS-3","nct_id":"NCT03684694","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lotis-3-nct03684694. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"A standard 3+3 dose escalation design will be used. The dose-limiting toxicity (DLT) period will be the 21 days following the first dose of ibrutinib. The dose escalation cohort will receive loncastuximab tesirine for Cycle 1 and 2 (3 weeks each) with concurrent ibrutinib (concomitant therapy) daily. Participants may continue to receive ibrutinib therapy up to 1 year after Cycle 1 Day 1 (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered intravenously (IV).","label":"Phase 1: Dose-Escalation of ADCT-402","type":"EXPERIMENTAL"},{"description":"Participants with non-germinal center B-cell diffuse large B-cell lymphoma (Non-GCB DLBCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered IV.","label":"Phase 2: MTD or RP2D of ADCT-402 in Non-GCB DLBCL","type":"EXPERIMENTAL"},{"description":"Participants with germinal center B-cell diffuse large B-cell lymphoma (GCB DLBCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered IV.","label":"Phase 2: MTD or RP2D of ADCT-402 in GCB DLBCL","type":"EXPERIMENTAL"},{"description":"Participants with mantle cell lymphoma (MCL) will receive the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of loncastuximab tesirine, as determined in Phase 1, once every 3 weeks for Cycle 1 and 2 and a daily dose of ibrutinib. Participants can continue treatment up to 1 year (once every 4 weeks from Cycle 3 onwards). Loncastuximab tesirine will be administered IV.","label":"Phase 2: MTD or RP2D of ADCT-402 in MCL","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2022-11-08","type":"ACTUAL"},"conditions":["Diffuse Large B-Cell Lymphoma","Mantle Cell Lymphoma"],"enrollment":{"count":136,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Loncastuximab Tesirine","otherNames":["Zynlonta","ADCT-402"],"type":"DRUG"},{"name":"Ibrutinib","otherNames":[],"type":"DRUG"}],"last_update":"2024-02-06","lead_sponsor":"ADC Therapeutics S.A.","official_title":"A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)","overall_status":"TERMINATED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2022-11-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)","timeFrame":"Day 1 until 30 days after last dose; max duration of treatment was 686 days for Phase 1 (up to approximately 716 days total)"},{"measure":"Phase 1: Number of Participants With Serious TEAEs","timeFrame":"Day 1 until 30 days after last dose; max duration of treatment was 686 days for Phase 1 (up to approximately 716 days total)"},{"measure":"Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)","timeFrame":"21 days"},{"measure":"Phase 1: Number of Participants With Dose Interruptions","timeFrame":"Up to a maximum of 686 days"},{"measure":"Phase 1: Number of Participants With Dose Reductions","timeFrame":"Up to a maximum of 686 days"},{"measure":"Phase 2: Complete Response Rate (CRR)","timeFrame":"Up to approximately 38 months"}],"references":[],"start_date":{"date":"2018-12-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma","url":"https://clinicaltrials.gov/study/NCT03684694"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lotis-3-nct03684694"}